Rationale for randomised trials of prostate cancer screening

European Journal of Cancer

Volumn 35, Issue 2, 1999, Pages 262-271

  Alexander, F E ^a   Andriole, G L ^a   Aus, G ^a   Auvinen, A ^a   Beensterboer, P ^a   Blijenberg, B G ^a   Bonardi, R ^a   Buys, S ^a   Candas, B ^a   Ciatto, S ^a   Crawford, E D ^a   Demers, R ^a   De Koning, H J ^a   Denis, L ^a   Dijk, M A ^a   Figueiredo, F ^a   Gellman, E P ^a   Gohagan, J ^a   Hakama, M ^a   Hugosson, J ^a   Kirkels, W I ^a   Kranse, R ^a   Van der Kwast, Th H ^a   Lilja, H ^a   Maattanen, L ^a   Mandel, J ^a   Miller, A B ^a   Monteiro, H ^a   Nelen, V ^a   Oberman, A ^a   Paez, A ^a   Prorok, P C ^a   Reding, D ^a   Rietbergen, J W B W ^a   Rose, D B ^a   Sanchez, A B ^a   Schroder, F H ^a   Da Silva, E C ^a   Simpson, N ^a   Smith, P H ^a   Stadaert, B ^a   Stenman, U H ^a   Teppo, L ^a   Turkes, A ^a   Weissfeld, J L ^a   Yokochi, L ^a   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Prostate cancer; Prostate specific antigen (PSA); Randomised controlled trials; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; HUMAN; LIFE EXPECTANCY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

AGED; DATA INTERPRETATION, STATISTICAL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0033083961     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00379-7     Document Type: Review

References (12)

1. Auvinen A., Rietbergen J.B.W., Denis L.J., Schröder F.H., Prorok P.C. Prospective evaluation plan for randomized trials of prostate cancer screening. J Med Screening. 3:1996;97-104.
2. Adami H.O., Baron J.A., Rothman K.J. Ethics of a prostate cancer screening trial. Lancet. 343:1994;958-960.
3. Johansson J.E., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer. A prospective population-based study in Sweden. JAMA. 277:1997;467-471.
4. Hoedemaeker R.F., Rietbergen J.B.W., Kranse R., van der Kwast T.H., Schröder F.H. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European randomized study of screening for prostate cancer. World J Urol. 15:1997;339-345.
5. Dearnaley D.P., Melia J. Early prostate cancer - to treat or not to treat. Lancet. 349:1997;892-893.
6. Lu Yao G.L., Yao S.L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 349:1997;906-910.
7. Gann P.H., Hennekins C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J Am Med Ass. 273:1995;289-294.
8. Mettlin C.J., Murphy G.P. Why is the prostate cancer death rate declining in the United States? Cancer. 82:1998;249-251.
9. Labrie F, Candas B. Decrease of prostate cancer death by screening: first data from the Quebec prospective and randomized study. American Society of Clinical Oncology, Annual Meeting, 18 May, 1998.
10. P. Boyle, Commentary on "Decrease of prostate cancer death by screening: first data from the Quebec prospective and randomized study". American Society of Clinical Oncology, Annual Meeting, 18 May, 1998.
11. Nyström L., Rutqvist L.E., Wall S., et al. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet. 341:1993;973-978.
12. Krahn M.D., Mahoney J.E., Eckman M.H., et al. Screening for prostate cancer: a decision analytic view. JAMA. 272:1994;781-786.